Web-based references relating to the number under the disk sign, listed by page header
Epilepsy: diagnosis
171
B Pohlmann 2006 BMJ 332 Feb 11 339
[Link]; page 483
172; page J Neurol
Neurosurg Psychiatry 1999 May;66(5):561-8 Supratentorial cavernous haemangiomas
and epilepsy: a review of the literature and case series. Moran NF
[Link]; page 483
173
NICE 2004 advice
[Link]; page 483
Anti-epilepsy drugs (AEDs)
174
Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate
monotherapy in patients with epilepsy. Author: Kaminow L, Schimschock JR, Hammer
AE, Vuong A. Journal: Epilepsy Behav; 2003 Dec ; 4(6):659-66. PubMed ID:
14698699
[Link]; page 484
175; page
Rev Neurol. 2001 Feb 1-15;32(3):247--Use of lamotrigine in the treatment of
absence epilepsy crises--Mauri-Llerda JA
[Link]; page 484
176
Primary Care Guidelines for the Management of Females with Epilepsy; Royal
Society of Medicine [no link]; page 484
177 Primary Care Guidelines for the
Management of Females with Epilepsy; Royal Society of Medicine [no
link]; page 484
178 Epilepsia 2000;41 Suppl 2:S7-12 Sudden unexplained death
and injury in epilepsy. Ficker DM
[Link]; page 484
179; page
Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for
epilepsy in adults: a systematic review and economic evaluation. Author: Wilby
J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S,
O'Meara S, Sculpher M, Drummond M, Forbes C. Journal: Health Technol Assess;
2005 Apr ; 9(15):1-157, iii-iv. PubMed ID: 15842952.
[Link]; page 485
180
Zonisamide: a review of its use in the management of partial seizures in
epilepsy. Author: Frampton JE, Scott LJ. Journal: CNS Drugs; 2005 ;
19(4):347-67. PubMed ID: 15813651.
[Link]; page 485
181
M Gillick 2000 nejm 342 206
[Link]; page 485
182
M Gillick 2000 nejm 342 206
[Link]; page 485
183
Uncontrolled epilepsy following discontinuation of antiepileptic drugs in
seizure-free patients: a review of current clinical experience. Author: Schmidt
D, L"scher W. Journal: Acta Neurol Scand; 2005 May ; 111(5):291-300. PubMed ID:
15819708
[Link]; page 485
184
Drug Ther Bul 2003 41 ( June) 41 [no link]; page 485
Parkinson’s disease (PD) and parkinsonism
185 Exp Gerontol. 2003
Apr;38(4):397 mt4216C variant in linkage with the mtDNA TJ cluster may confer a
susceptibility to mitochondrial dysfunction resulting in an increased risk of
Parkinson's disease in the Irish--Ross O
[Link]; page 486
186
J Neurol Neurosurg Psychiatry. 2003 Feb;74(2):158-62. J Neurol Neurosurg
Psychiatry. 2003 Feb;74(2):148-9. Multidisciplinary rehabilitation for people
with Parkinson's disease: a randomised controlled study. Wade D
[Link]; page 486
187
Qigong exercise for the symptoms of Parkinson's disease: A randomized,
controlled pilot study. Journal: Mov Disord; 2005 Oct 14 ; ():. PubMed ID:
16229022.
[Link]; page 486
188
Scottish adult formulary 2005
[Link]; page 486
189
Sleep. 2002 Dec15;25(8):905-9. Modafinil for the treatment of daytime sleepiness
in Parkinson's disease: a double-blind, randomized, crossover,
placebo-controlled polygraphic trial. Hogl B
[Link]; page 486
190
Scottish adult formulary 2005
[Link]; page 487
191
Ropinirole therapy for Parkinson's disease. Author: Pahwa R, Lyons KE, Hauser
RA. Journal: Expert Rev Neurother; 2004 Jul ; 4(4):581-8. PubMed ID: 15853577.
[Link]; page 487
192
Drug Ther Bul 1995 33 49; page 487
193 No link available; page 487
194
Monoamine oxidase B inhibitors for early Parkinson's disease. Author: Macleod
AD, Counsell CE, Ives N, Stowe R. Journal: Cochrane Database Syst Rev; 2005 ;
(3):CD004898. PubMed ID: 16034956.
[Link]; page 487
195
Prescrire Int 2002 Aug;11(60):108-11 Selegiline: a second look. Six years later:
too risky in Parkinson's disease
[Link]; page 487
(footnote) Ann
Neurol. 2005 Feb;57(2):298-302. Intraputamenal infusion of glial cell
line-derived neurotrophic factor in PD: a two-year outcome study. Patel NK
[Link]; page 487
(footnote) Cell
therapy for Parkinson's disease: problems and prospects. Author: Bj"rklund A.
Journal: Novartis Found Symp; 2005 ; 265():174-86; discussion 187, 204-211.
(footnote) PubMed ID: 16050257.
[Link]; page 487
Multiple sclerosis (MS)
196;
Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Author:
Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM. Journal:
Neurology; 2003 Jun 24 ; 60(12):1949-54. PubMed ID: 12821738
[Link]; page 488
197
J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):730High incidence and prevalence
of multiple sclerosis in south east Scotland: evidence of a genetic
predisposition--Rothwell PM
[Link]; page 488
198
BMJ; page 2003;327:646 Multiple sclerosis Self reported stressful life events
and exacerbations in multiple sclerosis: prospective study--D Buljevac
[Link]; page 488
199
NEJM 349:139 2003 Antimyelin Antibodies as a Predictor of Clinically Definite
Multiple Sclerosis after a First Demyelinating Event--Thomas Berger
[Link]; page 488
200
Drugs. 2003;63(15):1525 Early intervention in multiple sclerosis : better
outcomes for patients and society? Flachenecker P
[Link]; page 488
201
"interferon 1a appears effective after 1st clinical MS event (if prior
subclinical lesions on MRI): CHAMPS 2000 NEJM 343 898; page 488
202 Title:
Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with
azathioprine or interferon beta in Spain. Author: Rubio-Terres C, Dominguez-Gil
Hurle A. Journal: Rev Neurol; 2005 Jun 16-30 ; 40(12):705-10. PubMed ID:
15973634
[Link]; page 488
203
[Update in multiple sclerosis treatment.] Author: Uria D. Journal: Neurologia;
2004 Dec ; 19 Suppl 2():8-21. PubMed ID: 16184497.
[Link]; page 488
204
MS criteria
[Link]; page 489
205
Whiting P 2006 BMJ 332 15 April page 875. Accuracy of MRI for the diagnosis of
multiple sclerosis: systemic review.
[Link]; page 489
206 Temporal
critteria [@11456302]
[Link]; page 489
(footnote) Multiple
sclerosis in eMedicine
[Link]; page 489
(footnote) Significance
of the Argyll Robertson pupil in clinical medicine. Author: Dacso CC, Bortz DL.
Journal: Am J Med; 1989 Feb ; 86(2):199-202. PubMed ID: 2643871.
[Link]; page 489
